Comparison of the Administration of 150 or 75 of Recombinant LH in Agonist ICSI Cycles Stimulated with Recombinant FSH in Women Aged 35-39: A Comparative Study

Overview

Journal J Reprod Infertil

Specialty Reproductive Medicine

Date 2024 Jan 2

PMID 38164428

Authors

Roberto Matorras

Fermin Aspichueta

Begona Prieto

Rosario Mendoza

Iker Malaina

Blanca Corral

Lorena Crisol

Alberto Vendrell

Antonia Exposito

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of the study was to assess whether the coadministration of 150 of recombinant LH instead of 75 in women aged 35-39 improves the results in agonist ICSI cycles stimulated with 300 of recombinant FSH.

Methods: In this study, two ovarian stimulation protocols coexisted which were identical except in the administered dose of recombinant LH, for which some patients received 150 (n=231) and some received 75 (n=216). Both groups received 300 of recombinant FSH. Gonadotropins were reimbursed by the National Health System. Statistical analysis was performed by Student's t test, χ, and ANCOVA. Significance level was established at p=0.05.

Results: The number of retrieved oocytes was slightly higher in the 300/150 group (9.06±5.53 . 8.61±5.11), but the differences were not significant. Results were similar with the number of metaphase II oocytes (7.18±4.86 . 6.72±4.72) and the number of fertilized oocytes (4.64±3.2 . 4.23±2.72). The per-transfer clinical pregnancy rates exhibited close similarity between both groups (32.84% . 32.46%), as did the per-transfer live birth rates (29.90% . 30.37%) and the implantation rate. The rate of hyperstimulation syndrome (OHSS) as well as the rate of cancellation due to OHHS risk was similar in both groups. There was also no difference in the miscarriage rate. When results were expressed by per started cycle or by oocyte pick-up, the results remained very similar in both groups.

Conclusion: In women aged 35-39 undergoing ovarian stimulation with recombinant FSH in agonist cycles, the coadministration of 75 or 150 of recombinant LH did not influence pregnancy rates. However, a slight increase in the number of retrieved oocytes should not be disregarded.

References

Matorras R, Urquijo E, Mendoza R, Corcostegui B, Exposito A, Rodriguez-Escudero F . Ultrasound-guided embryo transfer improves pregnancy rates and increases the frequency of easy transfers. Hum Reprod. 2002; 17(7):1762-6. DOI: 10.1093/humrep/17.7.1762. View

Mochtar M, Danhof N, Ayeleke R, van der Veen F, van Wely M . Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles. Cochrane Database Syst Rev. 2017; 5:CD005070. PMC: 6481753. DOI: 10.1002/14651858.CD005070.pub3. View

Balasch J, Fabregues F . LH in the follicular phase: neither too high nor too low. Reprod Biomed Online. 2006; 12(4):406-15. DOI: 10.1016/s1472-6483(10)61991-8. View

Bosch E, Labarta E, Crespo J, Simon C, Remohi J, Pellicer A . Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril. 2010; 95(3):1031-6. DOI: 10.1016/j.fertnstert.2010.10.021. View

Marchiani S, Tamburrino L, Benini F, Pallecchi M, Bignozzi C, Conforti A . LH supplementation of ovarian stimulation protocols influences follicular fluid steroid composition contributing to the improvement of ovarian response in poor responder women. Sci Rep. 2020; 10(1):12907. PMC: 7395161. DOI: 10.1038/s41598-020-69325-z. View

Humaidan P, Chin W, Rogoff D, DHooghe T, Longobardi S, Hubbard J . Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Hum Reprod. 2017; 32(3):544-555. PMC: 5850777. DOI: 10.1093/humrep/dew360. View

Vuong T, Phung H, Ho M . Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Hum Reprod. 2015; 30(5):1188-95. DOI: 10.1093/humrep/dev038. View

Conforti A, Esteves S, Humaidan P, Longobardi S, DHooghe T, Orvieto R . Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2021; 19(1):91. PMC: 8215738. DOI: 10.1186/s12958-021-00759-4. View

Freis A, Germeyer A, Jauckus J, Capp E, Strowitzki T, Zorn M . Endometrial expression of receptivity markers subject to ovulation induction agents. Arch Gynecol Obstet. 2019; 300(6):1741-1750. DOI: 10.1007/s00404-019-05346-y. View

10.

Zhang Y, Zhang C, Shu J, Guo J, Chang H, Leung P . Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis. Hum Reprod Update. 2020; 26(2):247-263. DOI: 10.1093/humupd/dmz046. View

11.

NyboeAndersen A, Humaidan P, Fried G, Hausken J, Antila L, Bangsboll S . Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial. Hum Reprod. 2007; 23(2):427-34. DOI: 10.1093/humrep/dem317. View

12.

Behre H, Howles C, Longobardi S . Randomized trial comparing luteinizing hormone supplementation timing strategies in older women undergoing ovarian stimulation. Reprod Biomed Online. 2015; 31(3):339-46. DOI: 10.1016/j.rbmo.2015.06.002. View

13.

Koloda Y, Korsak V, Rozenson O, Anshina M, Sagamonova K, Baranov I . Use of a recombinant human follicle-stimulating hormone:recombinant human luteinizing hormone (r-hFSH:r-hLH) 2:1 combination for controlled ovarian stimulation during assisted reproductive technology treatment: A real-world study of routine practice.... Best Pract Res Clin Obstet Gynaecol. 2022; 85(Pt B):134-148. DOI: 10.1016/j.bpobgyn.2022.01.009. View

14.

Filicori M . The role of luteinizing hormone in folliculogenesis and ovulation induction. Fertil Steril. 1999; 71(3):405-14. DOI: 10.1016/s0015-0282(98)00482-8. View

15.

Shoham Z . The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertil Steril. 2002; 77(6):1170-7. DOI: 10.1016/s0015-0282(02)03157-6. View

16.

Lisi F, Rinaldi L, Fishel S, Caserta D, Lisi R, Campbell A . Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertil Steril. 2005; 83(2):309-15. DOI: 10.1016/j.fertnstert.2004.07.969. View

17.

Xiong Y, Bu Z, Dai W, Zhang M, Bao X, Sun Y . Recombinant luteinizing hormone supplementation in women undergoing in vitro fertilization/ intracytoplasmic sperm injection with gonadotropin releasing hormone antagonist protocol: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2014; 12:109. PMC: 4255634. DOI: 10.1186/1477-7827-12-109. View

18.

Matorras R, Perez-Sanz J, Corcostegui B, Perez-Ruiz I, Malaina I, Quevedo S . Effect of vitamin E administered to men in infertile couples on sperm and assisted reproduction outcomes: a double-blind randomized study. F S Rep. 2021; 1(3):219-226. PMC: 8244364. DOI: 10.1016/j.xfre.2020.09.006. View

19.

Roman R, Mussarat N, Detti L . Ovarian Stimulation in Poor Responders: Have We Made Progress?. Curr Pharm Biotechnol. 2017; 18(8):614-618. DOI: 10.2174/1389201018666171002132853. View

20.

Barrenetxea G, Agirregoikoa J, Jimenez M, de Larruzea A, Ganzabal T, Carbonero K . Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertil Steril. 2007; 89(3):546-53. DOI: 10.1016/j.fertnstert.2007.03.088. View